The Optimal Anti-Thrombotic Regimen after Surgical Bioprosthetic Aortic Valve Replacement—Does it Really Matter?

Thromb Haemost 2019; 119(02): 189-190
DOI: 10.1055/s-0038-1677504

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Constantin von zur Mühlen

¹Department of Cardiology and Angiology I, University Heart Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

,

Wolfgang Bothe

²Department of Cardiovascular Surgery, University Heart Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany

,

Christoph Bode

¹Department of Cardiology and Angiology I, University Heart Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

References
1 An KR, Belley-Cote EP, Um KJ. , et al. Anti-platelet therapy versus anticoagulation after surgical bioprosthetic aortic valve replacement: a systematic review and meta-analysis. Thromb Haemost 2019 119. (02). Doi: 10.1055/s-0038-1676816
2 Baumgartner H, Falk V, Bax JJ. , et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
3 Reinöhl J, Kaier K, Reinecke H. , et al. Effect of availability of transcatheter aortic-valve replacement on clinical practice. N Engl J Med 2015; 373 (25) 2438-2447
4 Stachon P, Kaier K, Zirlik A. , et al. Development and results of transcatheter and surgical aortic valve replacement in Germany 2014 and 2015 [in German]. Dtsch Med Wochenschr 2018; 143 (23) e206-e212
5 Colli A, Verhoye JP, Heijmen R. , et al; ACTION Registry Investigators. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008; 33 (04) 531-536
6 Hemmrich M, Peterson ED, Thomitzek K, Weitz JI. Spotlight on unmet needs in stroke prevention: the PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thromb Haemost 2016; 116 (Suppl. 02) S33-S40
7 Windecker S, Tijssen J, Giustino G. , et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J 2017; 184: 81-87